NEW YORK and WALTHAM, Mass. — October 29, 2025 — Leads & Copy — Dianthus Therapeutics, Inc. (Nasdaq: DNTH) recently shared new data from the Phase 2 MaGic trial of claseprubart in generalized Myasthenia Gravis (gMG) at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting.
Harvard Medical School’s Dr. Pushpa Narayanaswami presented the successful Phase 2 MaGic trial data at AANEM for the first time at a medical conference. New data was also released during a Virtual Industry Forum titled Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition. This included a decline in MG-ADL at week 4 in the open-label extension (OLE) of -2.5 points and a QMG score reduction of -3.2 points for patients on placebo during the RCT who received only two doses of claseprubart 600mg/4mL Q2W. This suggests potential for Q4W dosing of 300mg/2mL.
Additionally, a subgroup analysis of patients enrolled in the MaGic trial with a QMG score ≥10 at baseline demonstrated an increase in MG-ADL treatment effect for 300mg/2mL Q2W to a 3-point difference from placebo. In vitro data also showed the benefits of upstream (active C1s with claseprubart) vs. downstream (C5 with ravulizumab) inhibition in the prevention of pro-inflammatory split products C3a and C3b.
Simrat Randhawa, MD, MBA, Executive Vice President and Head of R&D of Dianthus Therapeutics, said that this post hoc analysis is driving their decision to add a QMG inclusion criteria and a 300mg/2mL S.C. Q4W arm, in addition to a Q2W arm, in their Phase 3 MG study.
The claseprubart data presented at AANEM and an archived webcast of the virtual industry forum are available on the Dianthus Therapeutics website.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
Source: Dianthus Therapeutics, Inc.
